These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 33050010)

  • 1. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
    Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA-Expression of
    Eckstein M; Wirtz RM; Gross-Weege M; Breyer J; Otto W; Stoehr R; Sikic D; Keck B; Eidt S; Burger M; Bolenz C; Nitschke K; Porubsky S; Hartmann A; Erben P
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment.
    Ecke TH; Voß PC; Schlomm T; Rabien A; Friedersdorff F; Barski D; Otto T; Waldner M; Veltrup E; Linden F; Hake R; Eidt S; Roggisch J; Heidenreich A; Rieger C; Kastner L; Hallmann S; Koch S; Wirtz RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer.
    Razzaghdoust A; Ghajari M; Basiri A; Torbati PM; Jafari A; Fattahi MR; Salahi M; Mofid B
    Investig Clin Urol; 2021 May; 62(3):274-281. PubMed ID: 33943049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
    Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W
    BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Jütte H; Reike M; Wirtz RM; Kriegmair M; Erben P; Tully K; Weyerer V; Eckstein M; Hartmann A; Eidt S; Wezel F; Bolenz C; Tannapfel A; Noldus J; Roghmann F
    J Pers Med; 2021 May; 11(6):. PubMed ID: 34073233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?
    Gazquez C; Ribal MJ; Marín-Aguilera M; Kayed H; Fernández PL; Mengual L; Alcaraz A
    BJU Int; 2012 Nov; 110(9):1310-6. PubMed ID: 22416928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
    Taubert H; Eckstein M; Epple E; Jung R; Weigelt K; Lieb V; Sikic D; Stöhr R; Geppert C; Weyerer V; Bertz S; Kehlen A; Hartmann A; Wullich B; Wach S
    Cells; 2021 Jan; 10(1):. PubMed ID: 33467469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External validation of FXYD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes.
    Ramírez-Backhaus M; Fernández-Serra A; Rubio-Briones J; Cruz Garcia P; Calatrava A; Garcia Casado Z; Casanova Salas I; Rubio L; Solsona E; López-Guerrero JA
    Actas Urol Esp; 2015 Oct; 39(8):473-81. PubMed ID: 25920992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
    Krafft U; Tschirdewahn S; Hess J; Harke NN; Hadaschik B; Olah C; Krege S; Nyirády P; Szendröi A; Szücs M; Módos O; Székely E; Reis H; Szarvas T
    Urol Oncol; 2019 Nov; 37(11):810.e7-810.e15. PubMed ID: 31053526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
    Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
    Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
    Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
    Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy.
    Sikic D; Eckstein M; Wirtz RM; Jarczyk J; Worst TS; Porubsky S; Keck B; Kunath F; Weyerer V; Breyer J; Otto W; Rinaldetti S; Bolenz C; Hartmann A; Wullich B; Erben P
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.